ICD-10 F18 Inhalant Codes: Abuse,

The F18 category — inhalant related disorders — covers the volatile solvents, aerosols, glues, and fuels inhaled for intoxication (“huffing”). It is the rarest substance family on adult SUD charts, but it skews heavily adolescent, which gives it outsized importance for youth residential and IOP programs — and brings documentation requirements (guardian consent, school coordination, safeguarding) that no other F10–F19 family carries.

Like F16, this family has an accuracy trap competitors gloss over: F18 contains no withdrawal codes. It also carries a code no other substance family has — inhalant-induced persisting dementia at the abuse stem.

All codes below verified against the FY2026 ICD-10-CM tabular list ( CMS ICD-10-CM files ↗ ), effective October 1, 2025. Part of the ICD-10 behavioral health directory.

F18 at a glance

The FY2026 tabular lists one inclusion term under the F18 category heading: volatile solvents. In clinical practice the family covers toluene-based glues and paints, gasoline and other fuels, aerosol propellants, cleaning fluids, and similar inhaled hydrocarbons (see NIDA’s inhalants overview ↗ for substance context).

One classification caveat: nitrite inhalants (“poppers”) are handled differently in DSM-5-TR. DSM-5-TR’s inhalant use disorder is limited to hydrocarbon-type volatile inhalants and places nitrites with the “other (or unknown) substance” class (paraphrased) — which maps to F19, not F18. The FY2026 ICD-10-CM index does not carry a distinct entry for amyl nitrite abuse. Nitrous oxide misuse similarly tends to be documented under other/unknown substance. When the chart says “poppers” or “whippets,” query rather than defaulting to F18.

The three stems

Complete F18 code table (FY2026)

F18.1- — Inhalant abuse

F18.2- — Inhalant dependence

F18.9- — Inhalant use, unspecified

All 39 codes above are billable in FY2026.

No withdrawal codes — and a dementia code no sibling has

Two structural notes worth stating plainly:

Patient uses multiple substances? Inhalant use in adolescents frequently co-occurs with cannabis and alcohol. Each documented substance gets its own code — there is no polysubstance shortcut. See the F19 guide for the rule.

• There are no F18.x3 withdrawal codes. The FY2026 tabular contains none, and DSM-5-TR likewise recognizes no inhalant withdrawal syndrome (paraphrased). If “inhalant withdrawal” appears in a chart, query the provider — the symptoms usually belong to a co-occurring substance.
• F18 carries persisting dementia at every stem (F18.17, F18.27, F18.97), reflecting the well-documented neurotoxicity of chronic solvent exposure. F18 also lacks the perceptual-disturbance intoxication codes (no F18.122/.222/.922) and the sexual-dysfunction and sleep-disorder induced codes that F15 and F19 carry.

Hierarchy and remission rules

When documentation mentions more than one severity level for inhalants, the ICD-10-CM Official Guidelines, Section I.C.5.b.2 ( FY2026 guidelines ↗ ), assign a single code:

Remission codes (F18.11, F18.21, F18.91) require the provider’s explicit documentation per Section I.C.5.b.3 — mild use disorder in early or sustained remission maps to F18.11, moderate/severe to F18.21 (paraphrased from the guideline mapping).

Adolescent documentation and safeguarding

Inhalant use concentrates in early adolescence — household products are accessible, cheap, and legal to possess — which means F18 diagnoses usually arrive wrapped in minor-consent and safeguarding obligations the code itself doesn’t capture. Programs documenting F18 diagnoses should build these into the chart:

• Consent and guardian involvement. State minor-consent statutes vary on whether adolescents can consent to SUD treatment without a guardian, and federal confidentiality rules under 42 CFR Part 2 govern what programs may disclose to parents and schools. Document the consent basis for treatment and every disclosure authorization explicitly.
• School-linked referrals. Inhalant cases often surface through school discipline or counselor referral. Document the referral source, information-sharing agreements, and any coordination plan — these support both continuity of care and medical-necessity narratives for structured outpatient levels.
• Safety assessment. Sudden sniffing death syndrome and hypoxic injury are documented risks of acute inhalant use; intake assessments should record use patterns (substance, method, frequency, setting) and an explicit risk discussion.
• Cognitive screening. Given the persisting-dementia codes, baseline cognitive screening at intake (and re-screening if chronic heavy use is documented) both serves the patient and substantiates any F18.x7 code a provider assigns.

Billing and medical necessity

F18-anchored claims are uncommon enough that payers look closely. Three patterns keep them clean:

• Co-occurring coding. Most inhalant cases at treatment facilities carry additional substance and mental health diagnoses. Code all documented conditions — an adolescent IOP claim supported by F18.10 plus cannabis use disorder plus an adjustment disorder tells a defensible medical-necessity story; F18.10 alone may not.
• Level-of-care logic. Adolescent residential and IOP claims ( H0017 – H0019 for residential, H0015 / H0035 for IOP/PHP) should connect inhalant-specific risks — cognitive effects, accessibility of household products at home, safeguarding gaps — to the placement decision, ideally in ASAM-dimension terms. See our guide to ASAM criteria and payer authorization.
• Assessment and counseling services. Initial assessment bills under H0001 or 90791; individual and group counseling under H0004 / H0005 or psychotherapy CPT codes.

Treatment planning

There are no approved medications for inhalant use disorder; treatment is behavioral, family-involved, and environmental. Plans for adolescent inhalant cases typically include family therapy components, environmental controls (securing household products), school re-engagement objectives, and cognitive monitoring where heavy use is documented. Write objectives a utilization reviewer can score — frequency of use, school attendance, family-session completion — using the structure in our treatment plan templates and SMART goals guide.

FAQ

What is the ICD-10 code for inhalant abuse? F18.10 (uncomplicated). Intoxication adds characters: F18.120 uncomplicated intoxication, F18.121 with delirium.

What is the ICD-10 code for inhalant use disorder? Mild → F18.1- (F18.10 uncomplicated); moderate/severe → F18.2- (F18.20); severity undocumented → F18.90.

Is there inhalant withdrawal in ICD-10? No. F18 has no withdrawal codes in the FY2026 code set, and DSM-5-TR does not recognize an inhalant withdrawal syndrome.

What about huffing paint or glue? Volatile solvents are the core of F18 — the category’s named inclusion term. Code by documented severity and complications.

Where do “poppers” (nitrites) code? DSM-5-TR places nitrite inhalants outside the inhalant class, which points coding toward F19 (other psychoactive substance) rather than F18 — query the provider and verify against current guidance.

EHR supports adolescent-program documentation, treatment planning, and claims for behavioral health facilities. Learn about the EHR or request a demo.

• CMS, FY2026 ICD-10-CM Code Descriptions and Tabular List (effective Oct 1, 2025) — cms.gov/medicare/coding-billing/icd-10-codes ↗ (accessed 2026-06-12)
• CMS, FY2026 ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.5.b — fy-2026-icd-10-cm-coding-guidelines.pdf ↗ (accessed 2026-06-12)
• CDC/NCHS, ICD-10-CM — cdc.gov/nchs/icd/icd-10-cm ↗ (accessed 2026-06-12)
• NIDA, Inhalants research topic — nida.nih.gov/research-topics/inhalants ↗ (accessed 2026-06-12)

Reference tables

Common questions

Official sources

• CMS ICD-10-CM filescms.gov
• NIDA’s inhalants overviewnida.nih.gov
• FY2026 guidelinescms.gov
• cdc.gov/nchs/icd/icd-10-cmcdc.gov